mRNA vaccination in breast cancer: current progress and future direction
Authors:
- 26 April 2023
- journal article
- review article
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 149 (11) , 9435-9450
Abstract
Messenger RNA (mRNA) vaccination has proven to be highly successful in combating Coronavirus disease 2019 (COVID-19) and has recently sparked tremendous interest. This technology has been a popular topic of research over the past decade and is viewed as a promising treatment strategy for cancer immunotherapy. However, despite being the most prevalent malignant disease for women worldwide, breast cancer patients have limited access to immunotherapy benefits. mRNA vaccination has the potential to convert cold breast cancer into hot and expand the responders. Effective mRNA vaccine design for in vivo function requires consideration of vaccine targets, mRNA structures, transport vectors, and injection routes. This review provides an overview of pre-clinical and clinical data on various mRNA vaccination platforms used for breast cancer treatment and discusses potential approaches to combine appropriate vaccination platforms or other immunotherapies to improve mRNA vaccine therapy efficacy for breast cancer.Keywords
Funding Information
- National Natural Science Foundation of China (82230057, 82061148016, 82272859, 81872141, 82230057, 82061148016, 82272859, 81872141)
This publication has 76 references indexed in Scilit:
- Active immunotherapy for mouse breast cancer with irradiated whole-cell vaccine expressing VEGFR2Oncology Reports, 2013
- Polyclonal HER2-specific antibodies induced by vaccination mediate receptor internalization and degradation in tumor cellsBreast Cancer Research, 2012
- Designer Lipids Advance Systemic siRNA DeliveryMolecular Therapy, 2010
- High immunogenic potential of p53 mRNA-transfected dendritic cells in patients with primary breast cancerBreast Cancer Research and Treatment, 2010
- Nanoparticles target distinct dendritic cell populations according to their sizeEuropean Journal of Immunology, 2008
- Adoptive cell transfer: a clinical path to effective cancer immunotherapyNature Reviews Cancer, 2008
- Human Breast Cancer Cells Selected for Resistance to Trastuzumab In vivo Overexpress Epidermal Growth Factor Receptor and ErbB Ligands and Remain Dependent on the ErbB Receptor NetworkClinical Cancer Research, 2007
- Alphaviral vector-transduced dendritic cells are successful therapeutic vaccines against neu-overexpressing tumors in wild-type miceVaccine, 2007
- A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancerBreast Cancer Research and Treatment, 2006
- Cotransfection of dendritic cells with RNA coding for HER-2/neu and 4-1BBL increases the induction of tumor antigen specific cytotoxic T lymphocytesCancer Gene Therapy, 2005